Nektar Therapeutics (NASDAQ:NKTR) had its price objective increased by Mizuho from $30.00 to $45.00 in a report released on Tuesday morning. They currently have a buy rating on the biopharmaceutical company’s stock.
Several other brokerages have also recently commented on NKTR. ValuEngine upgraded shares of Nektar Therapeutics from a sell rating to a hold rating in a research report on Friday, September 1st. William Blair restated an outperform rating on shares of Nektar Therapeutics in a research report on Tuesday, July 18th. Jefferies Group LLC restated a buy rating and issued a $23.00 target price on shares of Nektar Therapeutics in a research report on Friday, July 21st. Cowen and Company assumed coverage on shares of Nektar Therapeutics in a research report on Tuesday, November 7th. They issued an outperform rating for the company. Finally, BidaskClub cut shares of Nektar Therapeutics from a hold rating to a sell rating in a research report on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $35.58.
Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up $0.06 during trading on Tuesday, reaching $44.99. 3,675,856 shares of the company’s stock traded hands, compared to its average volume of 1,638,298. Nektar Therapeutics has a twelve month low of $11.41 and a twelve month high of $46.98. The company has a quick ratio of 3.99, a current ratio of 4.14 and a debt-to-equity ratio of 2.91.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The business had revenue of $152.90 million during the quarter, compared to analysts’ expectations of $126.50 million. During the same quarter in the previous year, the company earned ($0.32) EPS. The business’s revenue was up 321.2% on a year-over-year basis. equities research analysts expect that Nektar Therapeutics will post -0.75 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/11/17/mizuho-raises-nektar-therapeutics-nktr-price-target-to-45-00-2.html.
In related news, SVP Ivan P. Gergel sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $24.14, for a total transaction of $2,414,000.00. Following the completion of the transaction, the senior vice president now directly owns 84,871 shares in the company, valued at approximately $2,048,785.94. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO John Nicholson sold 15,910 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $37.78, for a total transaction of $601,079.80. Following the transaction, the chief operating officer now owns 249,066 shares of the company’s stock, valued at $9,409,713.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 941,427 shares of company stock valued at $24,663,626. 6.10% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Nektar Therapeutics by 14.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 692 shares in the last quarter. LS Investment Advisors LLC increased its position in Nektar Therapeutics by 8.8% during the 2nd quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 535 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new stake in Nektar Therapeutics during the 3rd quarter worth approximately $129,000. Mark Sheptoff Financial Planning LLC grew its holdings in Nektar Therapeutics by 79.4% during the 3rd quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock worth $146,000 after acquiring an additional 2,700 shares during the last quarter. Finally, Flinton Capital Management LLC grew its holdings in Nektar Therapeutics by 75.7% during the 2nd quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 3,392 shares during the last quarter. Institutional investors and hedge funds own 94.97% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.